GlassScriptPhysician profile
Kyung Min Hwang
NPI 1467299685
$602.48
in general payments reported to CMS, 2019-2025
11 companies · $342 in 2025
The $342 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $261 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $602.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $602.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $125.59 | 2025 | Austedo Xr |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $119.95 | 2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $78.77 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.33 | 2024 | Jardiance |
| Lundbeck LLC | $45.58 | 2025 | Rexulti |
| Electromed, INC. | $40.04 | 2024-2025 | Smartvest |
| Mallinckrodt Hospital Products INC. | $34.02 | 2024 | Acthar |
| Glaxosmithkline, LLC. | $33.24 | 2025 | Trelegy Ellipta |
| Actelion Pharmaceuticals US, INC. | $24.52 | 2024 | Opsumit, Uptravi |
| Pfizer INC. | $20.27 | 2024 | |
| Lilly USA, LLC | $14.17 | 2024 | Mounjaro, Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyung Min Hwang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.